Improvement of myocardial blood flow by lipid‐lowering therapy with pravastatin is modulated by apolipoprotein E genotype

References

• Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler Thromb 1993; 13: 1291–98
   PubMedGoogle Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• DiCorleto P. E., Gimbrone M. A. Vascular endothelium. Atherosclerosis and coronary artery disease, V Fuster, R Ross, E. J Topol. Lippincott‐Raven, Philadelphia 1996; 387–99
   Google Scholar
• Hutchins G. D., Schwaiger M., Rosenspire K. C., Krivokapich J., Schelbert H., Kuhl D. E. Noninvasive quantification of regional blood flow in the human heart using N‐13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990; 15: 1032–42
   PubMed Web of Science ®Google Scholar
• Laine H., Raitakari O. T., Niinikoski H., Pitkänen O. P., Iida H., Viikari J., et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998; 32: 147–53
   PubMed Web of Science ®Google Scholar
• Pitkänen O. P., Nuutila P., Raitakari O. T., Rönnemaa T., Koskinen P. J., Iida H., et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998; 47: 248–54
   PubMedGoogle Scholar
• Pitkänen O. P., Nuutila P., Raitakari O. T., Porkka K., Iida H., Nuotio I., et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 1999; 99: 1678–84
   PubMed Web of Science ®Google Scholar
• Mahley R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622–30
   PubMed Web of Science ®Google Scholar
• Utermann G., Hees M., Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977; 269: 604–7
   PubMed Web of Science ®Google Scholar
• Smith J. D. Apolipoprotein E4: an allele associated with many diseases. Ann Med 2000; 32: 118–27
   PubMed Web of Science ®Google Scholar
• Lehtimäki T., Moilanen T., Viikari J., Åkerblom H. K., Ehnholm C., Rönnemaa T., et al. Apolipoprotein E phenotypes in Finnish youths: a cross‐sectional and 6‐year follow‐up study. J Lipid Res 1990; 31: 487–95
   PubMed Web of Science ®Google Scholar
• Sing C. F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37: 268–85
   PubMed Web of Science ®Google Scholar
• Wilson P. W., Schaefer E. J., Larson M. G., Ordovas J. M. Apolipoprotein E alleles and risk of coronary disease. A meta‐analysis. Arterioscler Thromb VascBiol 1996; 16: 1250–5
   PubMed Web of Science ®Google Scholar
• Ilveskoski E., Perola M., Lehtimäki T., Laippala P., Savolainen V., Pajarinen J., et al. Age‐dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle‐aged men: an autopsy study. Circulation 1999; 100: 608–13
   PubMed Web of Science ®Google Scholar
• Judson R., Brain C., Dain B., Windemuth A., Ruano G., Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C‐reactive protein in dyslipidemic individuals. Atherosclerosis 2004; 177: 345–51
   PubMed Web of Science ®Google Scholar
• Rontu R., Ojala P., Hervonen A., Goebeler S., Karhunen P. J., Nikkilä M., et al. Apolipoprotein E genotype is related to plasma levels of C‐reactive protein and lipids and to longevity in nonagenarians. Clin Endocrinol (Oxf) 2006; 64: 265–70
   PubMed Web of Science ®Google Scholar
• Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7
   PubMed Web of Science ®Google Scholar
• Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–22
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
   PubMed Web of Science ®Google Scholar
• Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherfor J. D., Cole T. G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9
   PubMed Web of Science ®Google Scholar
• Treasure C. B., Klein J. L., Weintraub W. S., Talley J. D., Stillabower M. E., Kosinski A. S., et al. Beneficial effects of cholesterol‐lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481–7
   PubMed Web of Science ®Google Scholar
• Gould K. L., Martucci J. P., Goldberg D. I., Hess M. J., Edens R. P., Latifi R., et al. Short‐term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994; 89: 1530–8
   PubMed Web of Science ®Google Scholar
• Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol‐lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99: 2871–5
   PubMedGoogle Scholar
• Gerdes L. U., Gerdes C., Kervinen K., Savolainen M., Klausen I. C., Hansen P. S., et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101: 1366–71
   PubMed Web of Science ®Google Scholar
• Ballantyne C. M., Herd J. A., Stein E. A., Ferlic L. L., Dunn J. K., Gotto A. M Jr., et al. Apolipoprotein E genotypes and response of plasma lipids and progression‐regression of coronary atherosclerosis to lipid‐lowering drug therapy. J Am Coll Cardiol 2000; 36: 1572–8
   PubMed Web of Science ®Google Scholar
• Janatuinen T., Laaksonen R., Vesalainen R., Raitakari O., Lehtimäki T., Nuutila P., et al. Effect of lipid‐lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001; 38: 561–8
   PubMed Web of Science ®Google Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low‐density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Hixson J. E., Vernier D. T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545–8
   PubMed Web of Science ®Google Scholar
• Clark J. C., Crouzel C., Meyer G. J., Strijckmans K. Current methodology for oxygen‐15 production for clinical use. Int J Rad Appl Instrum 1987; 38: 597–600
   PubMedGoogle Scholar
• Crouzel C., Clark J., Brihaye C., . Radiochemistry automation for PET. Radiopharmaceuticals for positron emission tomography, G Stöckling, V Pike, et al. Kluwer Academic Publishers, The Netherlands 1993; 45–90
   Google Scholar
• Iida H., Kanno I., Takahashi A., Miura S., Murakami S., Takahashi K., et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron‐emission tomography. Strategy for quantification in relation to the partial‐volume effect. Circulation 1988; 78: 104–15
   PubMed Web of Science ®Google Scholar
• Iida H., Takahashi A., Tamura Y., Ono Y., Lammertsma A. A. Myocardial blood flow: comparison of oxygen‐15‐water bolus injection, slow infusion and oxygen‐15‐carbon dioxide slow inhalation. J Nucl Med 1995; 36: 78–85
   PubMed Web of Science ®Google Scholar
• Iida H., Rhodes C., de Silva R., Araujo L. I., Bloomfield P. M., Lammertsma A. A., et al. Use of the left ventricular time‐activity curve as a noninvasive input function in dynamic oxygen‐15‐water positron emission tomography. J Nucl Med 1992; 33: 1669–77
   PubMed Web of Science ®Google Scholar
• O'Malley J. P., Illingworth D. R. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990; 39: 150–4
   PubMed Web of Science ®Google Scholar
• Ojala J. P., Helve E., Ehnholm C., Aalto‐Setälä K., Kontula K. K., Tikkanen M. J. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemia. J Intern Med 1991; 230: 397–405
   PubMed Web of Science ®Google Scholar
• John S., Schlaich M., Langenfeld M., Weihprecht H., Schmidt G., Weidinger G., et al. Increased bioavailability of nitric oxide after lipid‐lowering therapy in hypercholesterolemic patients: a randomized, placebo‐controlled, double‐blind study. Circulation 1998; 98: 211–16
   PubMed Web of Science ®Google Scholar
• Laufs U., La Fata V., Plutzky J., Liao J. K. Upregulation of endothelial nitric oxide synthase by HMG‐CoA reductase inhibitors. Circulation 1998; 97: 1129–35
   PubMed Web of Science ®Google Scholar
• Miyata M., Smith J. D. Apolipoprotein E allele‐specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta‐amyloid peptides. Nat Genet 1996; 14: 55–61
   PubMed Web of Science ®Google Scholar
• Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 1996; 34: 599–608
   PubMedGoogle Scholar
• Ridker P. M. High‐sensitivity C‐reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004; 148: S19–26
   Google Scholar
• Leipert B., Becker B. F., Gerlach E. Different endothelial mechanisms involved in coronary responses to known vasodilators. Am J Physiol 1992; 262: H1676–83
   Google Scholar
• Mayhan W. G. Endothelium‐dependent responses of cerebral arterioles to adenosine 5'‐diphosphate. J Vasc Res 1992; 29: 353–8
   PubMed Web of Science ®Google Scholar
• Buus N. H., Bottcher M., Hermansen F., Sander M., Nielsen T. T., Mulvany M. J. Influence of nitric oxide synthase and adrenergic inhibition on adenosine‐induced myocardial hyperemia. Circulation 2001; 104: 2305–10
   PubMed Web of Science ®Google Scholar
• Wilson R. F., Wyche K., Christensen B. V., Zimmer S., Laxson D. D. Effects of adenosine on human coronary arterial circulation. Circulation 1990; 82: 1595–606
   PubMed Web of Science ®Google Scholar